| Patient | Muhammad Ali |
|---|---|
| Date of birth | 1972-01-17 |
| Identifiers | MRN HR-BX001-SYN; SSN (made up) 000-01-7724 |
| Document date | 2026-02-10 |
| Author | Celeste Moreau, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for Parkinson's disease: motor, non-motor, fall-risk, and orthostatic assessment [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1981 | Professional boxing career with repeated blows to the head, ended by retirement in 1981; whether it caused his Parkinson's disease is disputed | R (CLM-0003, CLM-0006) |
| 1984 | Parkinsonian condition diagnosed in 1984, at 42, by a neurologist in New York, with slowness of movement, a masked face, decreased blinking, tremor, and a shuffling gait | D (CLM-0003, CLM-0004) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily | One tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m. | Oral route | 2014-10-01 to 2026-03-10 | completed | S |
Positive for the concerns in the history of present illness. Alert and fully oriented; humorous and engaged; speech soft and slow but fluent and coherent; MoCA 27 of 30. Mood good; PHQ-9 score 3; no hallucinations or delusions. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. At the first visit, in the on state about two hours after a levodopa dose: Hoehn and Yahr stage 2.5; MDS-UPDRS Part III 30. Bilateral bradykinesia and rigidity, worse on the right; right-hand rest tremor; reduced facial expression and blinking; soft, monotone speech; reduced arm swing with short steps; recovers unaided on the pull test after three steps. No dyskinesia, wearing-off, or freezing. Falls: none in the past year and no near falls; Timed Up and Go 13 seconds without an aid. Orthostatic check at the first visit: 130/80 mmHg, pulse 70, after 5 minutes supine; 122/78 mmHg, pulse 76, after 3 minutes standing, without symptoms; no orthostatic hypotension. Non-motor screens at the first visit: EAT-10 swallowing screen 2 (below the threshold of 3), no choking or coughing with meals; no dream enactment on the RBD screening questionnaire; Epworth Sleepiness Scale 6; no constipation, urinary urgency, or lightheadedness; no hallucinations; impulse-control screen (QUIP-RS) negative. Independent in all activities of daily living; buttoning and handwriting are slow; drives only short local trips in daylight. [S]
Vital signs recorded on 2026-02-10; see the Vital Signs section. Mental status: Alert and fully oriented; humorous and engaged; speech soft and slow but fluent and coherent; MoCA 27 of 30; Mood good; PHQ-9 score 3; no hallucinations or delusions. The physical examination is limited to the findings relevant to this synthetic episode. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 191 | cm | S |
| 2026-02-10 | Body weight | 102 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 72 | /min | S |
| 2026-02-10 | Respiratory rate | 14 | /min | S |
| 2026-02-10 | Body temperature | 36.7 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-02-10 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-10 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-10 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-10 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-10 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 512 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-10 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-02-10 | Total score [MoCA] | 27 | {score} | S | ||
| 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations | active | confirmed | G20.A1 | S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic. |
| Hypokinetic dysarthria with soft speech due to Parkinson's disease | active | confirmed | R47.1 | S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic. |